ArticleAnnals of surgery2018
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma.
Article in Annals of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 124 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed.
- Characteristics and predictors of survival outcomes of patients with large pathology-defined T1b hepatocellular carcinoma undergoing resection.Updates in surgery · 2026Article
- Refining the role of liver transplantation as a curative treatment for hepatocellular carcinoma.International journal of clinical oncology · 2026Review
- Antiviral therapy is associated with achievement of statistical cure of patients undergoing liver resection for hepatocellular carcinoma: a retrospective study.Updates in surgery · 2026Article
- Article
- MRI radiomics combined with clinical factors to predict vessels encapsulating tumor clusters and early recurrence in hepatocellular carcinoma (≤ 3 cm).BMC medical imaging · 2026Article
- A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- A novel prognostic model based on MVIRGs identifies ANGPT2 as a key target driving the malignant progression of HCC.Biological procedures online · 2026Article
- Perioperative immunotherapy to reduce recurrence in resectable hepatocellular carcinoma - lessons learned from the CARES-009 trial.JHEP reports : innovation in hepatology · 2026Article
- Neoadjuvant or conversion therapy nullifies the prognostic impact of surgical margin width in hepatocellular carcinoma: a single-center retrospective study.BMC surgery · 2026Article
- Gambogic acid ameliorates hepatocellular carcinoma by inhibiting oxidative stress via Nrf2-pSmad2C/2L pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Artificial Intelligence in Scientific Writing: Balancing Innovation and Efficiency with Integrity: Perspectives and Position Statements of Global Andrology Forum Expert Group.The world journal of men's health · 2026Article
- LncRNA ZFAS1 in hepatocellular carcinoma: A systematic review of molecular mechanisms and clinical translation.Non-coding RNA research · 2026Review
- Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation.Cancer medicine · 2026Article
- The impact of microvascular invasion in tumor recurrence and survival after liver resection for non-B non-C hepatocellular carcinoma: a multicenter, propensity score-matched analysis.Surgical endoscopy · 2026Article
- Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.Cancer biology & medicine · 2026Review
- An interpretable machine learning model using routine clinical data for early recurrence prediction in hepatocellular carcinoma.Scientific reports · 2026Article
- Neoadjuvant therapy for hepatocellular carcinoma: emerging combinations and biomarker challenges.Frontiers in immunology · 2026Review
- Preoperative prediction of microvascular invasion in hepatocellular carcinoma ≤5 cm based on contrast-enhanced ultrasound features and LI-RADS categorization: a multicenter study.Frontiers in oncology · 2026Article
- Effect of oral probiotics on postoperative nutrition level of patients with liver cancer.Open medicine (Warsaw, Poland) · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to estimate probabilities of achieving the statistical cure from hepatocellular carcinoma (HCC) with hepatic resection (HR) and liver transplantation (LT).
backgroundStatistical cure occurs when the mortality of a specific population returns to values of that of general population. Resection and transplantation are considered potentially curative therapies for HCC, but their effect on the residual entire life-expectancy has never been investigated.
methodsData from 3286 HCC patients treated with LT (n = 1218) or HR (n = 2068) were used to estimate statistical cure. Disease-free survival (DFS) was the primary survival measure to estimate cure fractions through a nonmixture model. Overall survival (OS) was a secondary measure. In both, patients were matched with general population by age, sex, year, and race/ethnicity. Cure variations after LT were also adjusted for different waiting-list drop-outs.
resultsConsidering DFS, the cure fraction after LT was 74.1% and after HR was 24.1% (effect size >0.8). LT outperformed HR within all transplant criteria considered (effect size >0.8), especially for multiple tumors (>0.9) and even in presence of a drop-out up to 20% (>0.5). Considering OS, the cure fraction after LT marginally increased to 75.8%, and after that HR increased to 40.5%. The effect size of LT over HR in terms of cure decreased for oligonodular tumors (<0.5), became small for drop-out up to ∼20% (<0.2), and negligible for single tumors <5 cm (∼0.1).
conclusionAs other malignancies, statistical cure can occur for HCC, primarily with LT and secondarily with HR, depending on waiting-list capabilities and efficacy of tumor recurrence therapies after resection.
Indexed as
Identifiers
30080736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.